Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24079194 | 0.93 | KCNA2 (0.31) | EGFRKCNA2KCNA5KCNA1HTR2A | |
| SCHEMBL6125174 | 0.80 | PPARG (0.41) | EGFRHTR2AHTR2CALOX5CA12 | |
| SCHEMBL6125183 | 0.79 | CA9 (0.44) | EGFRKCNA2KCNA5KCNA1HTR2A | |
| SCHEMBL6125173 | 0.77 | EGFR (0.40) | MCHR1EGFRHTR2AHTR2CALOX5 | |
| SCHEMBL20370154 | 0.77 | LMNA (0.42) | EGFRHTR2AHTR2CALOX5PTGS1 | |
| SCHEMBL20370010 | 0.75 | EGFR (0.40) | MCHR1EGFRALOX5PTGS1PTGS2 | |
| SCHEMBL17409114 | 0.67 | PPARG (0.44) | HTR2AHTR2CCA12CA1CA2 | |
| SCHEMBL19167952 | 0.66 | CA9 (0.47) | KCNA2KCNA5KCNA1HTR2AHTR2C | |
| SCHEMBL17409115 | 0.64 | HTR2A (0.39) | KCNA2KCNA5KCNA1HTR2AHTR2C | |
| SCHEMBL19035744 | 0.64 | LMNA (0.45) | EGFRHTR2AHTR2CCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669244-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-02 | — | — | US | disclosed |
| US-9884830-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669244-B2 | Synthesis of tetracyclines and analogues thereof | TET1, TET3, MYC | MCHR1 3300/4885EGFR 833/4885KCNA2 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.